EISAI INITIATES PHASE 2 CLINICAL TRIAL TO EVALUATE LEMBOREXANT IN THE TREATMENT OF IRREGULAR SLEEP-WAKE RHYTHM DISORDER (ISWRD) IN DEMENTIA PATIENTS (Purdue Pharma LP)

(Source: Purdue Pharma LP) WOODCLIFF LAKE, N.J., and STAMFORD, Conn, Oct. 31, 2016 - Eisai and Purdue Pharma L.P. announced today the initiation of a multi-center, randomized Phase 2 clinical study (Study 202) to evaluate Eisai's internally-discovered oral dual orexin receptor antagonist lemborexant (E2006) in patients with mild to moderate Alzheimer's disease dementia (AD) who suffer from Irregular Sleep-Wake Rhythm Disorder (ISWRD). Lemborexant is being jointly developed by Eisai and Purdue Pharma L.P. ISWRD, often observed in patients with AD, is a type of circadian rhythm disorder, where there is no clear 24-hour sleep-wake pattern resulting in sleeping and waking occurring at irregular,...